Liquid Biopsy Market – Analysis and Forecasts from 2017 to 2025 Liquid Biopsy Market - Global Industry Analysis, S

Liquid
Biopsy
Market
-
Global
Industry
Analysis, Size, Share, Growth, Trends, and
Forecast 2017 - 2025
Liquid biopsy is a rapid plasma genotyping technique, which provides overview of
karyotypic abnormalities in the circulating tumor cells present in the blood sample.
The solid-tissue biopsies are used in cancer diagnostics; however, the liquid biopsy
technique is rapidly gaining momentum due to its minimal invasiveness. The liquid
biopsy field is a result of years of research for identification of cancer biomarkers,
and many of its highly promising detection subjects, such as extracellular vesicles,
are yet to be fully developed for their commercial applications. These are point-of-
care sequencing-based techniques, and the important insights obtained from
studies of liquid biopsy subjects have quickened the development of cancer
diagnostics.
View
Report
market.html
@
http://www.transparencymarketresearch.com/liquid-biopsy-
The emerging trend in the liquid biopsy field is the development of in-depth
analytical cancer diagnostic studies for cancer prognosis and metastasis of some
cancer types whose conventional tissue biopsies are complicated to carry out. The
global liquid biopsy market is driven by superior technological innovations of new
tests designed for cancer state monitoring, with increased sensitivities for
circulating tumor cells, along with its minimum invasiveness, superiority in genetic
anomaly detection than solid tumor biopsies, and increasing awareness through
social initiatives. However, issues with reimbursement policies and changing
governmental policies are expected to restrain the market.
The liquid biopsy market has been segmented based on biomarker type, cancer
type, test type, application, and end-user. In terms of biomarker type, the market
has been classified into circulating tumor DNA (ctDNA), circulating tumor cell (CTC),
extracellular vesicle (EV), and other biomarkers. Liquid biopsy was first developed
using circulating tumor cells, and since then most of the tests have been developed
using these biomarkers. Currently, the number of clinical trials for ctDNA analysis
are increasing because the concentration of ctDNA in the blood stream is higher as
compared to CTC. This is expected to reflect in the changing dynamics of the market
during the forecast period. Based on cancer type, the market has been divided into
lung cancer, blood cancer, breast cancer, liver cancer, prostate cancer, and others.
In terms of test type, the global liquid biopsy market is bifurcated into single gene